Otezla (Apremilast), an Oral PDE-4 Inhibitor, Receives FDA Approval for the Treatment of Patients with Active Psoriatic Arthritis and Plaque Psoriasis

Ítems similars

• Jardiance (Empagliflozin), an SGLT2 Inhibitor, Receives FDA Approval for the Treatment of Patients with Type 2 Diabetes
  per: Fala, Loretta
  Publicat: (2015)
• Apremilast (Otezla): A New Oral Treatment for Adults With Psoriasis and Psoriatic Arthritis
  per: Zerilli, Tina, et al.
  Publicat: (2015)
• Cosentyx (Secukinumab): First IL-17A Antagonist Receives FDA Approval for Moderate-to-Severe Plaque Psoriasis
  per: Fala, Loretta
  Publicat: (2016)
• Zontivity (Vorapaxar), First-in-Class PAR-1 Antagonist, Receives FDA Approval for Risk Reduction of Heart Attack, Stroke, and Cardiovascular Death
  per: Fala, Loretta
  Publicat: (2015)
• Update on the treatment of psoriasis and psoriatic arthritis – role of apremilast
  per: Forchhammer, Stephan, et al.
  Publicat: (2015)